Celecoxib Versus Diclofenac in Mild to Moderate Depression Management Among Breast Cancer Patients: A Double-Blind, Placebo-Controlled, Randomized Trial

Celecoxib Versus Diclofenac in Mild to Moderate Depression Management Among Breast Cancer Patients A Double-Blind, Placebo-Controlled, Randomized Trial

Background: Depression is a well-known complication of breast cancer, which is known to adversely affect quality of life, prognosis, and survival in breast cancer patients. Celecoxib, a nonsteroidal anti-inflammatory drug, which acts via the selective inhibition of cyclo-oxygenase (COX)-2, has been...

Full description

Saved in:
Bibliographic Details
Published in:The Annals of pharmacotherapy Vol. 49; no. 9; pp. 953 - 961
Main Authors: Mohammadinejad, Payam, Arya, Pantea, Esfandbod, Mohsen, Kaviani, Ahmad, Najafi, Masoome, Kashani, Ladan, Zeinoddini, Atefeh, Emami, Seyed Amirhossein, Akhondzadeh, Shahin
Format: Journal Article
Language:English
Published: Los Angeles, CA SAGE Publications 01-09-2015
Subjects:
Analgesics - therapeutic use
Antidepressive Agents - therapeutic use
Breast Neoplasms - psychology
Celecoxib - therapeutic use
Cyclooxygenase 2 Inhibitors - therapeutic use
Cyclooxygenase Inhibitors - therapeutic use
Depression - drug therapy
Depression - psychology
Diclofenac - therapeutic use
Double-Blind Method
Female
Humans
Middle Aged
Quality of Life
COX-2 inhibitors
anti-inflammatory agents
depression
celecoxib
diclofenac
breast neoplasms
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Depression is a well-known complication of breast cancer, which is known to adversely affect quality of life, prognosis, and survival in breast cancer patients. Celecoxib, a nonsteroidal anti-inflammatory drug, which acts via the selective inhibition of cyclo-oxygenase (COX)-2, has been shown to have antidepressive effects. Objectives: Here, we aimed to compare the efficacy and safety of celecoxib, a selective inhibitor of COX-2, with diclofenac, a nonselective inhibitor of both COX-1 and COX-2 in reducing depressive symptoms and pain in breast cancer patients. Methods: A total of 52 outpatients with breast cancer with mild to moderate depression, who suffered from pain and needed analgesics, participated in the trial and underwent 6 weeks of treatment with either celecoxib (200 mg twice daily) or diclofenac (50 mg twice daily). Participants were investigated using the Hamilton Depression Rating Scale (HDRS). The primary outcome measure was to compare the antidepressant effects of celecoxib and diclofenac. Results: Repeated-measures analysis demonstrated significant effect for Time × Treatment interaction on the HDRS scores: F(1.76, 87.85) = 9.66; P < 0.001. By study conclusion, greater improvement was observed in the HDRS score of the celecoxib group compared with the diclofenac group (P = 0.002). No one experienced remission (HDRS ≤ 7) in either group. Frequencies of adverse events were not significantly different between groups. Conclusion: Celecoxib seems to possess superior antidepressive effects compared with diclofenac in breast cancer patients with mild to moderate depression.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-News-1
ObjectType-Feature-3
content type line 23
ISSN:1060-0280
1542-6270
DOI:10.1177/1060028015592215